Notably, silencing YAP sensitizes CC cells to cisplatin, enhances their apoptotic response, and reduces their tumorigenic potential in vivo (95), suggesting that combination therapies targeting AJUBA and YAP could improve treatment outcomes. Here, YAP1 is linked to cholangiocarcinoma.